Year-long belapectin has limited efficacy in NASH patients with cirrhosis, portal hypertension
Consistent and long-term administration of belapectin is safe but has limited efficacy in patients with nonalcoholic steatohepatitis (NASH), cirrhosis and portal hypertension, a new study has found.
Year-long belapectin has limited efficacy in NASH patients with cirrhosis, portal hypertension
18 Apr 2020